Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 79,211 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

RJV001 Study in Adults Receiving Abdominoplasty

NCT04821648
View directory record Official record
Conditions
Submental Fat (SMF), Double Chin
Interventions
RJV001, Placebo
Drug
Lead sponsor
Rejuven Dermaceutical Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

NCT00656578
View directory record Official record
Conditions
Pain
Interventions
4975, Placebo
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Bakersfield, California • Owings Mills, Maryland • Austin, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated May 4, 2009 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Positive Prevention PLUS Program

NCT02540278
View directory record Official record
Conditions
Pregnancy in Adolescence
Interventions
Positive Prevention PLUS
Behavioral
Lead sponsor
California State University, San Bernardino
Other
Eligibility
12 Years to 19 Years
Enrollment
4,267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2015 · Synced Oct 28, 2026, 9:33 AM EDT
Recruiting No phase listed Observational

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

NCT04923178
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)

NCT00304278
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), Radiation Therapy (RAD)
Drug · Radiation
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

NCT01000285
View directory record Official record
Conditions
Leukemia-Lymphoma, Adult T-Cell
Interventions
Bortezomib, Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide, Raltegravir
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Miami, Florida • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors

NCT00084643
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
GTI-2040, oxaliplatin, capecitabine, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Oct 28, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional

Autologous Fresh Fat Grafting Followed by Autologous Cryopreserved Fat Grafting

NCT06747715
View directory record Official record
Conditions
Facial Defect
Interventions
Serial Fat Grafting Fresh followed by Cryopreserved Fat
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Satisfaction During Outpatient Versus Inpatient Foley Catheter Induction of Labor

NCT02975167
View directory record Official record
Conditions
Induction of Labor Affected Fetus / Newborn, Cervical Ripening, Patient Satisfaction
Interventions
Outpatient Cervical Ripening, Inpatient Cervical Ripening, Foley catheter placement, Pre-Foley Questionnaire, Post-Foley Questionnaire, Fetal Non-Stress Test
Other · Procedure · Behavioral
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 28, 2026, 9:33 AM EDT
Withdrawn Phase 4 Interventional

Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes

NCT03580967
View directory record Official record
Conditions
Type2 Diabetes, Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
Todd Doyle
Other
Eligibility
40 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 28, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional

A Randomized Controlled Trial of Impact of Wearable, Wireless Breast Pumps on Frequency and Efficacy of Milk Expression in Mothers of Premature Infants

NCT06723067
View directory record Official record
Conditions
Premature Birth
Interventions
Wearable wireless breast pump
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High in Front-of-package Label Pretest

NCT06227507
View directory record Official record
Conditions
Understanding of Food Nutrient Content
Interventions
Front-of-package label
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 99 Years
Enrollment
4,052 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy of YOUR SUPER Detox Bundle to Improve Perceived Well Being and Promote Adaptation of Healthy Dietary Choices

NCT05303207
View directory record Official record
Conditions
Eating Habit, Healthy Diet
Interventions
YOUR SUPER Detox Bundle
Dietary Supplement
Lead sponsor
Your Super, INC.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Rilonacept for Treatment of Familial Mediterranean Fever (FMF)

NCT00582907
View directory record Official record
Conditions
Familial Mediterranean Fever
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
4 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Madera, California • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

NCT00749892
View directory record Official record
Conditions
Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8, Stage 0a Ureter Cancer AJCC v8, Stage 0a Urethral Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage 0is Renal Pelvis Cancer AJCC v8, Stage 0is Ureter Cancer AJCC v8, Stage 0is Urethral Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Erlotinib Hydrochloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

NCT03011892
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Birmingham, Alabama • Bryant, Arkansas • Encino, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00507936
View directory record Official record
Conditions
Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
Interventions
ABT-894, placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 28, 2026, 9:33 AM EDT
Completed No phase listed Observational

Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina

NCT03253211
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
4,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 28, 2026, 9:33 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial

NCT04115644
View directory record Official record
Conditions
Full Thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions
Ketorolac, Marcaine (placebo), Kenalog
Drug
Lead sponsor
Michael Khazzam
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

NCT00000671
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
70
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

NCT05467709
View directory record Official record
Conditions
Health Volunteers
Interventions
Midazolam, CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 28, 2026, 9:33 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

NCT02092909
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
IMO-8400
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Fayetteville, Arkansas • Los Angeles, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 28, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia

NCT00497809
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
AVI-014 versus Filgrastim
Drug
Lead sponsor
AviGenics
Industry
Eligibility
18 Years and older · Female only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Anaheim, California • Greenbrae, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 28, 2026, 9:33 AM EDT